MINNEAPOLIS, March 18, 2011 /PRNewswire/ -- BridgePoint Medical, Inc., a Minnesota based medical device company, has announced that Denis Harrington has joined the company as President and Chief Executive Officer. A seasoned medical device executive with nearly two decades of experience in the cardiology industry, Harrington will lead BridgePoint's global commercialization of its CrossBoss™ Catheter and Stingray™ System.
Harrington comes to BridgePoint from Boston Scientific and Scimed where he spent the last 18 years. He is a veteran medical device sales leader with over 22 years in the med-tech business and for the last 7 years was head of US Sales for Boston Scientific's Cardiovascular and CRM businesses. Harrington has extensive experience in building, merging and growing sales, sales operations and broad commercial organizations.
"I look forward to leading the BridgePoint Medical team and building upon their successful development of innovative products for complex vascular disease," said Harrington.
Company Co-founder and previous President and General Manager, Chad Kugler, will continue to play an integral role at BridgePoint in his new position as Chief Operating Officer.
"Denis brings outstanding sales and marketing leadership in interventional vascular therapies to BridgePoint Medical. As we enter a new phase for the company I am confident that his expertise will enable our continued growth and ability to serve our customers and their patients successfully," said Kugler.
Denis is a 1983 graduate of the United States Military Academy at West Point. He served for 5 years in the Army, attaining the rank of Captain.
About BridgePoint Medical
BridgePoint Medical, Inc. is a privately held company established in 2006 to design, develop and commercialize new technologies and techniques to treat challenging coronary and peripheral artery disease. Investors include New Enterprise Associates, Polaris Venture Partners, Foundation Medical Partners and Michael Berman.
|SOURCE BridgePoint Medical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved